Gene · 7994
Papers1,720
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 1,720
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of KAT6A (MOZ) against leukemia by an isostere strategy. | Eur J Med Chem | 2023 | 37651878 | PubTator, text mining | PubMed |
| Histone Modification of Colorectal Cancer by Natural Products. | Pharmaceuticals (Basel) | 2023 | 37631010 | PubTator, text mining | PubMed |
| Plasmodium falciparum Development from Gametocyte to Oocyst: Insight from Functional Studies. | Microorganisms | 2023 | 37630530 | PubTator, text mining | PubMed |
| The Spectrum of Molecular Pathways in Gliomas-An Up-to-Date Review. | Biomedicines | 2023 | 37626776 | PubTator, text mining | PubMed |
| KLF12 transcriptionally regulates PD-L1 expression in non-small cell lung cancer. | Mol Oncol | 2023 | 37606530 | PubTator, text mining | PubMed |
| Therapeutic targeting of leukemia stem cells in acute myeloid leukemia. | Front Oncol | 2023 | 37601659 | PubTator, text mining | PubMed |
| The effects of acarbose treatment on cardiovascular risk factors in impaired glucose tolerance and diabetic patients: a systematic review and dose-response meta-analysis of randomized clinical trials. | Front Nutr | 2023 | 37599681 | PubTator, text mining | PubMed |
| SETD1A drives stemness by reprogramming the epigenetic landscape in hepatocellular carcinoma stem cells. | JCI Insight | 2023 | 37581938 | PubTator, text mining | PubMed |
| Epigenetic Factors and ncRNAs in Testicular Cancer. | Int J Mol Sci | 2023 | 37569569 | PubTator, text mining | PubMed |
| YY1 Knockdown Relieves the Differentiation Block and Restores Apoptosis in AML Cells. | Cancers (Basel) | 2023 | 37568827 | PubTator, text mining | PubMed |
| Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response. | Cancers (Basel) | 2023 | 37568822 | PubTator, text mining | PubMed |
| Concomitant PIK3CA and TP53 Mutations in Breast Cancer: An Analysis of Clinicopathologic and Mutational Features, Neoadjuvant Therapeutic Response, and Prognosis. | J Breast Cancer | 2023 | 37565929 | PubTator, text mining | PubMed |
| Advances in epigenetic research of adolescent idiopathic scoliosis and congenital scoliosis. | Front Genet | 2023 | 37564871 | PubTator, text mining | PubMed |
| Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer. | Cell Chem Biol | 2023 | 37557181 | PubTator, text mining | PubMed |
| Functions and mechanisms of protein lysine butyrylation (Kbu): Therapeutic implications in human diseases. | Genes Dis | 2023 | 37554202 | PubTator, text mining | PubMed |
| Systematic analysis of histone acetylation regulators across human cancers. | BMC Cancer | 2023 | 37553641 | PubTator, text mining | PubMed |
| Gain-of-function mutant p53 together with ERG proto-oncogene drive prostate cancer by beta-catenin activation and pyrimidine synthesis. | Nat Commun | 2023 | 37537199 | PubTator, text mining | PubMed |
| Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment. | Diagnostics (Basel) | 2023 | 37510143 | PubTator, text mining | PubMed |
| KAT6A::EP300 fusion in congenital myeloid sarcoma: Yet another novel molecular marker indicating spontaneous remission?: A case report. | Medicine (Baltimore) | 2023 | 37505185 | PubTator, text mining | PubMed |
| EMT Features in Claudin-Low versus Claudin-Non-Suppressed Breast Cancers and the Role of Epigenetic Modifications. | Curr Issues Mol Biol | 2023 | 37504297 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7994/papers?page=10